Stem cell outfits a winner in upcoming election

The nation's top biotech analysts have looked over the field of presidential candidates and announced a big winner: Stem cell companies. All of the three major presidential candidates have given their blessings to pumping up federal funding of research in the field--in a marked reversal to President Bush's steadfast stand on restricting funds related to embryonic stem cell research.

"Any candidate is going to have a better policy on stem cells than our current president," Ren Benjamin, biotech analyst for Rodman & Renshaw, tells CNNMoney. "If that's the case, then it will be good news not only for the companies working in the space, but for the space in general."

- read the CNNMoney report

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.